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A B S T R A C T
Background
Invasive fungal infections (IFIs) are important causes of morbidity and mortality in solid organ transplant recipients.
Objectives
This study aims to systematically identify and summarise the effects of antifungal prophylaxis in solid organ transplant recipients.
Search methods
The Cochrane Central Register of Controlled Trials, MEDLINE (from 1966), and EMBASE (from 1980) were searched. Reference
lists, abstracts of conference proceedings and scientific meetings (1998-2003) were handsearched. Authors of included studies and
pharmaceutical manufacturers were contacted.
Selection criteria
Randomised controlled trials (RCTs) in all languages comparing the prophylactic use of any antifungal agent or regimen with placebo,
no antifungal, or another antifungal agent or regimen.
Data collection and analysis
Two reviewers independently applied selection criteria, performed quality assessment, and extracted data using an intention-to-treat
approach. Differences were resolved by discussion. Data were synthesised using the random effects model and expressed as relative risk
(RR) with 95% confidence intervals (95% CI).
Main results
Fourteen unique trials with 1497 randomised participants were included. Antifungal prophylaxis did not reduce mortality (RR 0.90,
95% CI 0.57 to 1.44). In liver transplant recipients, a significant reduction in IFIs was demonstrated for fluconazole (RR 0.28, 95%
CI 0.13 to 0.57). Although less data were available for itraconazole and liposomal amphotericin B, indirect comparisons and one direct
comparative trial suggested similar efficacy. Fluconazole prophylaxis did not significantly increase invasive infections or colonisation
with fluconazole-resistant fungi. In renal and cardiac transplant recipients, neither ketoconazole nor clotrimazole significantly reduced
invasive infections. Overall, the strength and precision of comparisons however were limited by a paucity of data.
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Authors’ conclusions
For liver transplant recipients, antifungal prophylaxis with fluconazole significantly reduces the incidence of IFIs with no definite
mortality benefit. Given a 10% incidence of IFI, 14 liver transplant recipients would require fluconazole prophylaxis to prevent one
infection. In transplant centres where the incidence of IFIs is high, or in situations where the individual risk is great, antifungal
prophylaxis should be considered.
P L A I N L A N G U A G E S U M M A R Y
Antifungal drugs used for prevention can significantly reduce the number of invasive fungal infections in liver transplant
patients
Invasive fungal infections - infections of the bloodstream and organs within the body (e.g. meningitis, pneumonia, peritonitis) - are
important causes of morbidity andmortality in liver, pancreas, heart, kidney and lung (i.e. solid organ) transplant recipients. This review
found that fluconazole, used as a preventive drug, significantly reduced the number of invasive fungal infections in liver transplant
patients. More studies are needed to determine how effective antifungal drugs are for pancreas, heart, kidney and lung transplant
patients.
B A C K G R O U N D
Invasive fungal infections (IFIs) are an emerging problem and
an important cause of morbidity and mortality amongst the in-
creasing populations of immunocompromised and otherwise de-
bilitated patients. Amongst North American hospitalised patients
their incidence increased from 2.0 to 3.8 infections/1000 dis-
charges during the decade 1980 to 1990 (Beck-Sague 1993).
Patient groups at particular risk for IFIs include those with cancer
that have undergone chemotherapy and/or bone marrow trans-
plantation, solid organ transplant recipients, critically-ill patients
in Intensive Care Units, and very low birth weight neonates.
Amongst solid organ transplant recipients, IFIs remain a relatively
common and clinically important complication. The risk is great-
est during the early post-transplant period (Singh 2000) and varies
with transplant type; liver (7 to 42%), heart (5 to 21%), lung (15
to 35%), and pancreas (18 to 38%) transplant recipients are at
greater risk than renal transplant recipients (1 to 14%) (Paya 1993;
Singh 2000). Many other risk factors for the development of IFIs
have also been identified, including hepatic and renal dysfunction,
retransplantation, greater degrees of immunosuppression, surgical
complications, and post-transplant bacterial or cytomegalovirus
infections (Castaldo 1991; George 1997; Nieto-Rodriguez 1996;
Paya 1993; Patel 1996; Paterson 1999; Singh 2000).
Although a wide range of fungal pathogens cause IFIs in solid
organ transplant recipients, Candida and Aspergillus species ac-
count for the vast majority, with the former causing more than
three-quarters (Singh 2000). They include bloodstream and other
deep organ infections, such as peritonitis, hepatosplenic candidi-
asis, meningitis, and pneumonia. Invasive aspergillosis generally
presents within the first four weeks following transplantation. The
lungs are the most common initial site of infection, although dis-
semination to other organs, particularly the brain, occurs in more
than half (Paterson 1999). The clinical consequences of IFIs in
solid organ transplant recipients are considerable, with attributable
mortality rates reported as high as 70% for invasive candidiasis
(Nieto-Rodriguez 1996) and 100% for invasive aspergillosis de-
spite antifungal therapy (Paterson 1999).
IFIs are often diagnosed late because of their nonspecific clini-
cal features and the poor sensitivity and specificity of currently
available diagnostic tests. Given the high mortality and morbid-
ity associated with such infections, particularly where the insti-
tution of antifungal therapy is delayed, attention has focused on
preventative strategies. Antifungal prophylaxis with amphotericin
B, fluconazole, and itraconazole reduces IFIs in neutropenic pa-
tients (Gotzsche 2002; Kanda 2000). In these settings, antifun-
gal prophylaxis has become a standard strategy in high-risk neu-
tropenic patients. However, the benefit of antifungal prophylaxis
in high-risk non-neutropenic patients remains uncertain (Paya
2002; Singh 2000; Sobel 2001).
The prophylactic use of antifungal agents is associated with ac-
tual and potential problems. Although several antifungal agents
are available, the choice is not straightforward, as each has differ-
ing spectra of activity, pharmacological properties, toxicities, and
costs. Amphotericin B is active against a broad spectrum of fungi,
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but requires intravenous administration and is associated with re-
nal toxicity and infusion-related febrile reactions. Although lipid
preparations of amphotericin B have reduced toxicity (Johansen
2002), they are significantly more expensive. Azole antifungal
agents, such as ketoconazole, fluconazole, and itraconazole, may
be administered orally and are overall well tolerated, but have im-
portant interactions with many drugs, particularly immunosup-
pressant agents commonly used in solid organ transplantation.
Furthermore, ketoconazole and fluconazole are inactive againstAs-
pergillus species and other filamentous fungi and itraconazole has
poor gastrointestinal absorption.Nonabsorbable antifungal agents
given by the oral route, such as amphotericin B and nystatin, are
relatively nontoxic. Although their use is based on the rationale
that the most invasive Candida infections are derived from the
gastrointestinal tract colonisation (Nucci 2001), they have no ac-
tivity against other important portals of entry, such as the skin or
respiratory tract.
An important potential problem of antifungal prophylaxis re-
lates to selective pressure, whereby susceptible strains or species
of fungi are simply replaced by resistant ones. This phenomenon
is well-recognised in bacteria as a consequence of antibiotic use
(McGowan 1983). There is some evidence that increases in azole-
resistant invasive candida infections have resulted from increases
in azole use (Abi-Said 1997; Fortun 1997; Gleason 1997; Nguyen
1996). In HIV-positive patients, thrush with azole-resistant can-
dida strains and species has been selected for by azole use (Johnson
1995; Law 1994). Thus, antifungal prophylaxis in solid organ
transplant recipients requires consideration of toxicity, ecological
effects, resistance selection, and cost, as well as efficacy.
O B J E C T I V E S
To evaluate the benefits and harms of prophylactic antifungal
agents for the prevention of fungal infections in solid organ trans-
plant recipients.
The following primary questions were examined:
• Is prophylaxis with any antifungal agent(s) associated with
reduced IFIs and mortality compared with no prophylaxis?
• Are some agent(s) alone or in combination more efficacious
than others?
• For each agent, does the efficacy depend upon dose, route
of administration, and duration of prophylaxis?
• Do some patient subgroups derive greater benefit from
antifungal prophylaxis than others?
Secondary questions were examined:
• Is antifungal prophylaxis associated with reduced superficial
fungal infections?
• Is antifungal prophylaxis associated with colonisation or
infection with azole-resistant fungal strains or species?
• Is prophylaxis with antifungal agent(s) associated with
clinically-significant toxicity?
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) and quasi-RCTs that eval-
uate the effect of any prophylactic antifungal agent (alone or in
combination with other interventions) in solid organ transplant
recipients.
Types of participants
Studies involving patients who have received one or more solid
organ transplants (heart, lung, kidney, liver, or pancreas) were con-
sidered. Studies involving patients with neutropenia or HIV-in-
fected patients were excluded; the former patient group has al-
ready been the subject of a systematic review and the latter involves
a different spectrum of fungal infections. Where studies include
solid organ transplant recipients, together with neutropenic and/
or HIV-infected patients, they were included, providing the pro-
portion of the latter groups is less than 25%.
Types of interventions
Studies were considered if they involved the randomised compar-
ison of any antifungal agent with placebo, no antifungal, or an-
other antifungal agent, dose, route of administration, or duration.
The study groups were required to differ only for the antifungal
regimen under investigation; other aspects of care, including the
routine use of other prophylactic antimicrobial agents, should be
the same to avoid confounded comparisons. Secondary “preven-
tion” trials (i.e. trials examining antifungal agents to prevent the
relapse of an established fungal infection) were not considered, as
the objective of this review was to assess interventions to prevent
primary fungal infections.
Types of outcome measures
Primary outcome measures included:
• Proven IFI. The definition of proven IFI included a
compatible clinical illness with either histological evidence of IFI
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or a positive fungal culture from one or more deep/sterile site
specimen. Funguria (as indicated by a positive urine fungal
culture), in the absence of a complicated urinary tract infection,
and fungal oesophagitis was classified as superficial fungal
infections. The definitions used in individual studies however
were used, as they are likely to vary from study-to-study. Where
uncertainty regarding the definitions or the validity of the
classification of patients existed, authors were contacted for
clarification.
• Total mortality.
Secondary outcome measures included:
• Proven or suspected IFI. The definition of proven or
suspected IFI included all patients classified as proven IFI
together with those with possible infection. This was defined as
the initiation of systemic antifungal therapy without fulfilment
of the criteria for a proven IFI.
• Superficial fungal infection. Superficial fungal infections
were defined as superficial cutaneous, oropharyngeal,
oesophageal or uncomplicated urinary tract fungal infections.
• Fungal colonisation. Fungal colonisation was defined as a
positive culture from any body site for fungi from any site that
develops (if not present at baseline) or persists (if present at
baseline).
• Proven IFI caused by an azole-resistant Candida species
(defined as Candida glabrata, Candida krusei, or another species
with documented azole resistance) or a filamentous fungi
(including Aspergillus species).
• Fungal colonisation at any body site with azole-resistant
Candida species.
• Adverse events requiring cessation of study drug(s).
The time point of assessment of outcome measures was at three
months after commencement of prophylaxis or at the end of pro-
phylaxis (whichever is longer). All outcome measures were anal-
ysed according to intention-to-treat.
Search methods for identification of studies
Initial search
Relevant studies were identified by searching electronic databases
(Table 1 - Electronic search strategy) and other resources:
1. Cochrane Central Register of Controlled Trials (Issue 4,
2003)
2. MEDLINE (OVID: 1966-August 2003): the search
strategy incorporated the Cochrane highly sensitive search
strategy for identifying RCTs in MEDLINE (Dickersin 1994)
3. EMBASE (OVID: 1980-August 2003): the search strategy
incorporated a sensitive strategy for identifying RCTs in
EMBASE (Lefebvre 1996)
4. Proceedings of major relevant conferences (including, but
not limited to Interscience Conference of Antimicrobial Agents
and Chemotherapy, American Society for Microbiology,
Infectious Diseases Society of America, European Congress of
Clinical Microbiology and Infectious Diseases, and American
Society of Transplant Physicians)
5. Reference lists of identified studies and major reviews
6. Contact with researchers active in the field and primary
authors of identified relevant trials for details of unpublished
trials
7. Contact with manufacturers of the study drugs (including
Pfizer, Gilead, Merck) for additional published or unpublished
trials.
No language restrictions were applied. Letters, abstracts, and un-
published trials were accepted to reduce publication bias. If dupli-
cate publication was suspected, authors were contacted for clari-
fication, and if confirmed, the publication with the most and/or
the longest follow-up data was used for the review.
Review update
For this update the Cochrane Renal Group’s specialised register
and The Cochrane Central Register of Controlled Trials (CEN-
TRAL, inThe Cochrane Library) was searched. CENTRAL and the
Renal Group’s specialised register contain the handsearched results
of conference proceedings from general and speciality meetings.
This is an ongoing activity across the Cochrane Collaboration and
is both retrospective and prospective (http://www.cochrane.us/
masterlist.asp). Please refer toTheCochraneRenal ReviewGroup’s
Module in The Cochrane Library for the complete lis of nephrol-
ogy conference proceedings searched.
Date of most recent search: November 2005
Data collection and analysis
The review was undertaken by four reviewers (EGP, ACW, TCS,
JCC). The search strategy as above was devised and performed
to identify potentially relevant studies (EGP). Each subsequent
step of the selection and review process was then performed in-
dependently by two reviewers (EGP and ACW). The titles and
abstracts of identified studies were initially screened for eligibility.
Potentially eligible studies were then subjected to full text review
for methodological quality assessment (see below) and data extrac-
tion (see below). Reviewers were not be blinded to author, source
institution, or publication source of studies. Discrepancies were
resolved by discussion with two additional reviewers (TCS and
JCC).
Data extraction
Data were extracted and collected on a standardised paper form.
Where important data regarding study results were not provided
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in the primary papers, the authors were contacted for clarification.
Data was extracted wherever possible for all randomised patients
on an intention-to-treat basis. Data was then entered into RevMan
twice (EGP).
Evaluation of study methodological quality
The validity and design characteristics of each study was evalu-
ated for major potential sources of bias (generation of random
allocation sequence, allocation concealment, blinding, intention-
to-treat analysis, and completeness of follow-up) (Clarke 2001).
Each study quality factor was assessed separately, but not with a
composite score.
Randomised sequence generation
• Adequate: Random number generation used
• Unclear: No information on randomised sequence
generation available
• Inadequate: Alternate medical record numbers or other
nonrandom sequence generation
Allocation concealment
• Adequate (A): Allocation method described that would not
allow investigator/participant to know or influence intervention
group before eligible participant entered into study
• Unclear (B): No information on allocation method available
• Inadequate (C): Allocation method such as alternate
medical record numbers or unsealed envelopes, open allocation
sequence, or any information in the study that indicated that
investigators or participants could influence intervention group
Blinding
• Subjects: yes/no/not stated
• Investigators: yes/no/not stated
• Outcome assessors: yes/no/not stated
• Data analysis: yes/no/not stated
Intention-to-treat (ITT) analysis
• Yes: Specifically reported by authors that ITT analysis was
undertaken and confirmed on study assessment, or not stated but
evident from study assessment that ITT analysis was undertaken
• Unclear: Reported by authors that ITT analysis was
undertaken but unable to be confirmed on study assessment, or
not reported and unable to be confirmed on study assessment
• No: Lack of ITT analysis confirmed on study assessment
(patients who were randomised were not included in the analysis
because they did not receive study intervention, they withdrew
from the study, or were not included because of protocol
violation) regardless of whether ITT analysis was reported
Completeness of follow-up
Percentage of randomised participants with outcome data at de-
fined study endpoint
Data analysis
Dichotomous data was analysed using RR and 95% CI.
Heterogeneity in trial resultswas graphically inspected and assessed
with a test of homogeneity (χ² on N-1 degrees of freedom), with
P < 0.1 considered as indicating significant heterogeneity and with
a test of inconsistency (I²) (Higgins 2003). Potential causes for
significant heterogeneity, such as study design, drug type, drug
dose, drug administration route, population, outcome measure
definitions, or other factors were explored. Results from different
studies, where clinically appropriate, were pooled using a random
effects model and compared with the fixed effect model.
Subgroup analysis was performed to assess the influence of study
methodology quality and clinical parameters (such as type of an-
tifungal agent, dose and duration of prophylaxis, transplant type,
outcome measure definition, and follow-up duration). Although
variations in treatment effect may be explained by differences in
the background risk of developing IFIs, assessing this variation
through the simple relationship between the observed treatment
effect and the observed background risk in individual studies is
flawed (Davey Smith 2001; Sharp 2001).
Publication bias was assessed using a funnel plot (log relative risk
for efficacy versus 1/standard error) (Egger 1997).
R E S U L T S
Description of studies
From the initial search strategy (1926 potential studies), 114 stud-
ies were identified as potentially relevant and retrieved for further
assessment (Figure 1). Although pharmaceutical companies pro-
vided some information, no unique studies were identified from
that source. No useable data or information regarding one po-
tentially eligible study (Rossi 1995), available only as an abstract,
other than its title was able to be retrieved despite extensive efforts,
including contact with the corresponding author.
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Figure 1. Search strategy results
Twenty references reporting 14 trials (Biancofiore 2002; Gombert
1987; Keogh 1995; Lumbreras 1996; Meyers 1997; Owens 1984;
Patton 1994; Ruskin 1992; Sharpe 2003; Sobh 1995; Tollemar
1995; Tortorano 1995; Winston 1999; Winston 2002) involving
1497 randomised patients (range, 34 to 236 patients/study) were
included in the review. All studies were in English. One study was
available only as an abstract (Meyers 1997).
Eleven trials evaluated systemic antifungal agents. Ten trials com-
pared a systemic antifungal regimen with placebo, no antifun-
gal, or an oral nonabsorbable agent: four involved fluconazole
(Lumbreras 1996;Meyers 1997; Tortorano 1995;Winston 1999),
two itraconazole (Biancofiore 2002; Sharpe 2003), one liposo-
mal amphotericin B (Tollemar 1995), and three ketoconazole
(Keogh 1995; Patton 1994; Sobh 1995). One study directly
compared two systemic regimens: fluconazole versus itracona-
zole (Winston 2002). Additionally, one of the placebo-controlled
studies compared two different itraconazole-based regimens with
placebo (Biancofiore 2002), which we assessed both separately
and together. Three studies evaluated only oral nonabsorbable
agents: one compared clotrimazole with placebo (Owens 1984)
and two compared clotrimazole with nystatin (Gombert 1987;
Ruskin 1992). Nine studies involved liver transplant recipients
(Biancofiore 2002; Lumbreras 1996; Meyers 1997; Ruskin 1992;
Sharpe 2003; Tollemar 1995; Tortorano 1995; Winston 1999;
Winston 2002), four renal transplant recipients (Gombert 1987;
Owens 1984; Patton 1994; Sobh 1995), and one cardiac trans-
plant recipients (Keogh 1995).
Reporting of outcomes was variable (Table 2; Table 3). Total mor-
tality was reported for all but one of the trials assessing systemic
antifungal agents (Sobh 1995), but none of those assessing only
nonabsorbable agents. Eleven trials reported proven IFIs, with the
diagnostic criteria for this outcome provided in six of these. The re-
ported criteria was consistent with our definition in six (Lumbreras
1996; Sharpe 2003; Tollemar 1995; Tortorano 1995; Winston
1999; Winston 2002), but not in the other which included posi-
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tive cultures from three or more peripheral sites as evidence of an
invasive infection (Biancofiore 2002), which we would regard as
consistent with either colonisation or superficial infection. Of the
four trials without explicit criteria, three provided sufficient infor-
mation in the results to classify infections (Owens 1984; Patton
1994; Sobh 1995), but not the other, which was presented only
in abstract form (Meyers 1997). The other three trials (Gombert
1987; Ruskin 1992; Sobh 1995) did not report IFIs. Other out-
comes were even more variably reported, particularly with respect
to the fungal species causing infection and/or colonisation. Over-
all, most data were available for the fluconazole trials.
Risk of bias in included studies
Methodological quality parameters were incompletely reported for
most trials (Table 2; Table 3)
Random sequence generation
As reported, random sequence generation was adequate in three
trials (Gombert 1987; Lumbreras 1996; Winston 2002) and un-
clear in the other 11.
Allocation concealment
Allocation concealment was adequate in two trials (Sharpe 2003;
Tollemar 1995) and unclear in 12.
Blinding
Blinding of study participants was evident in six trials (Biancofiore
2002; Meyers 1997; Owens 1984; Sharpe 2003; Tollemar 1995;
Winston 1999), and of investigators in five (Meyers 1997; Owens
1984; Sharpe 2003; Tollemar 1995; Winston 1999). Three tri-
als reported that outcome assessors were blinded (Sharpe 2003;
Tollemar 1995; Winston 1999).
Intention-to-treat analysis
Intention-to-treat analysis was confirmed in seven trials (
Biancofiore 2002; Keogh 1995; Lumbreras 1996; Ruskin 1992;
Sobh 1995; Winston 1999; Winston 2002).
Completeness of follow-up
Post-randomisation exclusions were 10% or greater for two trials
(Patton 1994; Sharpe 2003; Tollemar 1995) and unstated for one
(Meyers 1997).
Effects of interventions
Systemic antifungal agents versus placebo/no
antifungal/nonabsorbable agents
Total mortality
Total mortality rates in the control arms of the trials ranged from
3 to 16% (mean, 12%). Total mortality was not reduced with
any systemic antifungal regimen compared with placebo, no treat-
ment, or nonabsorbable antifungal agents. Results were homoge-
neous across different antifungal agents and transplant types (χ² =
9.01, df = 8, P = 0.34, I² = 11.3%) . Pooled estimates for all trials
combined (Analysis 1.1: RR 0.90, 95% CI 0.57 to 1.44) and for
those in liver transplant recipients combined (RR 0.84, 95% CI
0.54 to 1.30) did not demonstrate a significant mortality benefit,
although confidence intervals were wide.
Proven invasive fungal infections (IFIs)
Fluconazole significantly reduced the risk of proven IFIs in liver
transplant recipients compared with placebo or nonabsorbable an-
tifungal agents by about three-quarters (Analysis 1.2.1: RR 0.28,
95% CI 0.13 to 0.57). The overall rate of proven infections in the
control arm of these four studies was 13% (range 4 to 23%). De-
spite differences in the prophylactic regimens, such as dose, route
of administration, and duration, the relative risk reductions across
these studies were homogeneous (χ² = 1.04, df= 3, P = 0.79; I² =
0%).
Proven IFIs were reported to occur in only one of the two itra-
conazole trials: in this, no significant reduction in infections was
demonstrated, although confidence intervals were wide (Analysis
1.2.2: RR 0.80, 95% CI 0.44 to 1.45).
Liposomal amphotericinBprevented all proven invasive infections
in one trial in liver transplant recipients, but similarly confidence
intervals were very wide (Analysis 1.2.3: RR 0.07, 95% CI 0.00
to 1.26).
No significantly heterogeneity was demonstrated amongst the
seven studies that compared fluconazole, itraconazole, or ampho-
tericin Bwith no antifungal or a nonabsorbable antifungal agent in
liver transplant recipients (χ² = 8.44, df = 5, P = 0.13, I² = 40.7%).
This suggests a similar underlying efficacy for the prevention of
proven IFIs in such patients, which is not critically dependent on
the antifungal agent, dose, duration, or route of administration
(pooled estimate, RR 0.39, 95% CI 0.18 to 0.85).
Ketoconazole did not significantly reduce infections in the single
study in renal transplant recipients (RR 7.67, 95% CI 0.32 to
182.44) and that in cardiac transplant recipients (RR 0.43, 95%
CI 0.09 to 2.93), although only a total of seven infections occurred
amongst 137 randomised patients in these two trials.
Proven or suspected invasive fungal infections
Fluconazole prophylaxis reduced the incidence of combined
proven and suspected IFIs (Analysis 1.7.1: RR 0.46, 95% CI 0.28
to 0.76). The incidence of suspected invasive infections (empiric
antifungal use) ranged from 3% to 8% in the control arms of
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these trials and was not significantly reduced by fluconazole pro-
phylaxis. In the single itraconazole study reporting this outcome,
the incidence of suspected infections was not significantly reduced
(Analysis 1.7.2: RR 0.25, 95% CI 0.03 to 1.93). Similarly, lipo-
somal amphotericin B did not significantly reduce the incidence
of suspected infections (Analysis 1.6.3: RR 1.27, 95% CI 0.30
to 5.34) or that of suspected and proven infections combined
(Analysis 1.7.3: RR 0.42, 95% CI 0.14 to 1.27). However, for
both of these studies, the confidence intervals were wide.
Superficial fungal infections
Fluconazole significantly reduced superficial fungal infections in
liver transplant recipients (Analysis 1.8.1: RR 0.24, 95% CI 0.10
to 0.59). Amongst these three studies, the overall rate of super-
ficial fungal infections was 29% (range, 25% to 31%), with no
significant heterogeneity in the effect of fluconazole prophylaxis
demonstrated (χ² = 3.9, df = 2, P = 0.14, I² = 48.8%). No super-
ficial infections occurred in the itraconazole arm of the single trial
reporting this outcome. Amongst renal transplant recipients, ke-
toconazole reduced superficial infections (RR 0.19, 95% CI 0.04
to 0.86), although the rate of superficial infections in the control
groups of these two studies were considerably different (18% and
64%) and heterogeneity was demonstrated between them (χ² =
2.83, df = 1, P = 0.09, I² = 64.7%). In the single study of keto-
conazole in cardiac transplant recipients, all superficial infections
were prevented.
Fungal colonisation
Fluconazole reduced fungal colonisation in liver transplant recipi-
ents (Analysis 1.9.1: RR 0.47, 95% CI 0.37 to 0.61). Results were
homogeneous across the three trials reporting this outcome (χ² =
1.58, df = 2, P = 0.45, I² = 0%). Itraconazole prophylaxis similarly
reduced colonisation (Analysis 1.9.2: RR 0.57, 95% CI 0.41 to
0.80), although only one study was available.
Infection and colonisation with azole-resistant fungi
Invasive infections with C. glabrata, C. krusei, or moulds were re-
ported in three fluconazole trials, causing 6% and 3% of invasive
infections in the control and fluconazole arms respectively.No sig-
nificant increase in their incidence was associated with fluconazole
(Analysis 1.5.1:RR 0.50, 95% CI 0.19 to 1.33). Based on single
studies, no significant increases were associated with itraconazole
(Analysis 1.5.2:RR 5.76, 95% CI 0.33 to 101.77), liposomal am-
photericin B (Analysis 1.5.3: RR 0.32, 95% CI 0.01 to 7.59), or
ketoconazole (Analysis 1.5.4: RR 0.58, 95% CI 0.11 to 3.13),
although confidence intervals were wide.
Fungal colonisation with C. glabrata or C. krusei was reported
in three fluconazole trials and occurred in 7% of patients in the
control arms and 16% in the fluconazole arms. In all three, C.
glabrata or C. krusei colonisation was greater in the fluconazole
arms, although the pooled effect was not significant (Analysis
1.10.1:RR 1.82, 95%CI 0.66 to 5.03). Itraconazole, in a single
study, did not increase such colonisation (Analysis 1.10.2:RR1.04,
95%CI 0.20 to 5.43).
Adverse effects (Analysis 1.11)
Adverse effects requiring cessation of systemic antifungal prophy-
laxis were very uncommon and did not occur more frequently
than in the control arms.
Subgroup and sensitivity analyses
Subgroup and sensitivity analyseswere performedusing the pooled
results from the seven studies assessing systemic antifungal agents
versus no antifungal in liver transplant recipients. No obvious
effect of reported study methodology quality, publication status,
or analysis method (random effects versus fixed effect model) was
evident (Table 4), although themagnitude of the risk reductionwas
greater for studies employing diagnostic criteria for IFIs that were
both explicit and consistent with our definitions than otherwise.
Direct comparisons of systemic antifungal agents
Two trials directly compared systemic antifungal prophylactic regi-
mens in liver transplant recipients: one compared itraconazolewith
fluconazole and the other intravenous liposomal amphotericin B
with fluconazole for one week, each followed by oral itraconazole
for three weeks. These studies did not demonstrate any significant
differences in total mortality, proven or proven or suspected IFIs,
superficial fungal infections, fungal colonisation, or adverse effects
requiring antifungal cessation (Analysis 2.1, Analysis 2.2, Analysis
2.7, Analysis 2.8, Analysis 2.9, Analysis 2.11). The incidence of
IFIs with filamentous fungi or azole-resistant Candida species and
of colonisation with azole-resistant Candida species were also sim-
ilar (Analysis 2.5, Analysis 2.10).
Nonabsorbable antifungal agents
Amongst liver transplant recipients, superficial fungal infections
were significantly reduced by clotrimazole compared with placebo
in the single available study (Analysis 3.8: RR 0.17, 95% CI 0.04
to 0.67). Although no proven IFIs in the clotrimazole arm, the
effectwas not significant given the small overall event rate (Analysis
3.2: RR 0.12, 95% CI 0.01 to 2.19).
In the two studies directly comparing clotrimazole with nystatin
in renal transplant recipients, no significant differences in the in-
cidence of superficial fungal infection, fungal colonisation, or ad-
verse effects were demonstrated (Analysis 4.8).
D I S C U S S I O N
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This meta-analysis demonstrates that antifungal prophylaxis with
fluconazole reduces IFIs in liver transplant recipients by about
three-quarters although only one of four trials individually demon-
strated a significant effect, the other three yielded a similar but
non-significant benefit. Furthermore, the efficacy of fluconazole
was remarkably consistent across the studies despite considerable
clinical heterogeneity (including differences in dose, duration, and
route of administration of fluconazole as well as the comparator
and underlying risk of infection) and methodological heterogene-
ity (including differences in diagnostic criteria and reported study
methodological parameters). This suggests that the pooled esti-
mates are robust and generalizable to a diverse range of clinical
settings. Assuming an overall average 10% incidence of IFI in liver
transplant recipients (Fung 2002), 14 patients would require flu-
conazole prophylaxis to prevent one infection (Table 5). For lower
risk recipients, with an approximate 5% incidence, this would in-
crease to 28 patients. However, for highest risk patients, such as
those undergoing retransplantation, and/or those with fulminant
hepatitis, preoperative immunosuppressive therapy, operative or
infective complications, with a risk of fungal infections around
25% (Collins 1994; George 1997; Patel 1996), only six patients
would require prophylaxis to prevent one fungal infection (Table
5).
Itraconazole and liposomal amphotericin B both have broader an-
tifungal spectra than fluconazole. Although neither agent demon-
strated a significant reduction in invasive infections (based on only
three studies), their efficacies are likely to be similar to that of flu-
conazole. The results of the single study directly comparing itra-
conazole with fluconazole reinforce this finding. No direct com-
parisons of liposomal amphotericin B with other antifungals are
available, although one study comparing liposomal amphotericin
B with fluconazole for one initial week - each then followed by
itraconazole for three weeks - demonstrated no significant dif-
ference (Winston 2002). Recently marketed systemic antifungal
agents, such as caspofungin and voriconazole, offer potential ad-
vantages, such as wider spectrum of activity, improved pharmaco-
logical properties, and greater safety, however no data are available
regarding their prophylactic efficacy. Given the demonstrated ef-
ficacy of fluconazole, the justification for the use of such broader-
spectrum agents depends on the incidence of infections with flu-
conazole-resistant pathogens. However from the trials reviewed
here and from other reports (Singh 2000), such infections account
for 25% or less of all invasive infections in solid organ transplant
recipients.
The significant reduction in IFIs in liver transplant recipients with
antifungal prophylaxis has not been confirmed in other settings,
such as heart, lung, or pancreas recipients, because of a lack of
formal evaluation in RCTs. Three trials, designed principally to
assess the cyclosporine-sparing effect of ketoconazole in cardiac
and renal transplant recipients, were available, did not demon-
strate a significant reduction in invasive infections. Although wide
confidence intervals reflected a very low event rate, poor bioavail-
ability and a lack of demonstrated efficacy in neutropenic patients
(Gotzsche 2002), would suggest little benefit for ketoconazole.
Similarly, despite limited data, nonabsorbable agents are unlikely
to be effective (Gotzsche 2002a).
Given the significant reduction in IFIs and their high attributable
mortality, the lack of significant mortality benefit associated with
antifungal prophylaxis is noteworthy. As the number of available
studies was limited, this result may reflect type II error. However,
there are other possible explanations for this finding. Patients at
risk of fungal infections most likely share risks for other serious
complications and may have died from other causes. It is also pos-
sible that any mortality benefit provided by antifungal prophy-
laxis was matched by the institution of early empirical antifungal
therapy in the control arm. The overall results are consistent with
those in neutropenic patients, where despite similar reductions in
IFIs, no significant mortality benefit was demonstrated for flu-
conazole or itraconazole, and only a marginal benefit was demon-
strated for amphotericin B (Gotzsche 2002). Although concerns
regarding possible increased mortality associated with fluconazole
prophylaxis in bone marrow transplant recipients have been raised
(Gotzsche 2002), there was no evidence of this amongst solid or-
gan transplant recipients. A reduction in fungal-related mortality
has been reported in a meta-analysis of fluconazole prophylaxis in
neutropenic patients (Kanda 2000). We did not assess this out-
come, as we, like others (Gotzsche 2002), considered the attribu-
tion of deaths to fungal infections too imprecise and subjective,
and therefore prone to bias, particularly in studies without blinded
outcome assessors.
The selection of resistant fungal species is a major potential ad-
verse consequence of widespread prophylactic antifungal use. Cer-
tain Candida species, such as C. glabrata and C. krusei, and
most moulds, including Aspergillus species, are intrinsically flu-
conazole-resistant. The de novo development of fluconazole-resis-
tance amongst susceptible species and the emergence of intrin-
sically resistant species have been associated with its use (Law
1994; Johnson 1995; Nguyen 1996; Abi-Said 1997; Fortun 1997;
Gleason 1997). Amongst the three fluconazole studies containing
sufficient information, no increase in fluconazole-resistant fungal
infections was demonstrated, although only eight infections with
fluconazole-resistant Candida spp. and ten with moulds were re-
ported. However, all three trials reported an increase, albeit non-
significant, in colonisation with C. glabrata and C. krusei. The
confidence intervals around the point estimates were very wide,
reflecting the relatively small event rate. Thus, given the relatively
small sample sizes in these studies, a significant effect of flucona-
zole on the either the spectrum of fungal species or their antifungal
susceptibility cannot be excluded. Further studies involving the
characterisation and susceptibility testing of fungal isolates, an ap-
propriate timeframe, and sufficient statistical power are therefore
required.
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Themajor limitationof this systematic review is the relatively small
number of trials and their small sample sizes causing imprecision
of pooled estimates. We sought to maximise our study retrieval
by employing a comprehensive search strategy encompassing the
major computerised databases without language restriction, major
conference proceedings, and review articles. Unpublished studies
(’grey literature’) were also sought despite the potential for inflated
estimates of intervention efficacy (McAuley 2000). We also ap-
proached major pharmaceutical companies marketing antifungal
agents, but identified no additional or unpublished studies. Pub-
lication bias was recognised previously in trials of antifungal pro-
phylaxis in neutropenic patients (Johansen 1999). Examination of
funnel plots for systemic antifungal agents versus control shows
asymmetry around the point estimate of effect (Figure 2; Figure
3), which may indicate publication bias.
Figure 2. Funnel plot for systemic antifungal agents versus placebo/no antifungal/nonabsorbable antifungal
agent; outcome=proven invasive fungal infections
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Figure 3. Funnel plot for systemic antifungal agents versus placebo/no antifungal/nonabsorbable antifungal
agent; outcome=mortality
The reporting of methodological quality of studies in this review
was generally suboptimal. Allocation concealment, an important
potential source of bias if inadequate (Schultz 1995), was adequate
in only one study. IFIs are often diagnosed with at least some de-
gree of uncertainty and subjectivity. Blinding of outcome assessors
with respect to treatment allocation would therefore be an im-
portant precaution to minimise bias, although this was reportedly
taken in only two studies. Despite progress toward standardisation
(Ascioglu 2002), a varied - and often conflicting - range of diag-
nostic criteria for IFIs have been published (Ascioglu 2001). This
problemwas evident amongst the studies reviewed here.We there-
fore, wherever possible, restricted the diagnosis to patients with
compatible clinical features in whom fungi were demonstrated in
blood or deep tissue specimens by histopathology and/or culture.
We classified uncomplicated funguria and fungal oesophagitis as
superficial, not invasive, infections. However one trial included
positive cultures of nonsterile specimens as evidence of invasive
infections and another did not provide either the criteria or suf-
ficient details to allow independent classification. Despite these
shortcomings in reported study methodology, they did not appear
to obviously influence the direction or magnitude of trial results.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Our results demonstrate that antifungal prophylaxis, particularly
with fluconazole, is effective in preventing IFIs in liver transplant
recipients. Although the optimal dose and duration of prophylaxis
remains uncertain, it should be considered particularly for high-
risk patients or in centres experiencing a high rate of IFIs. Given
that the risk of fungal infections in transplant recipients varies
from patient-to-patient, prophylaxis would be logically applied
selectively and individually according to that risk, rather than uni-
versally.
Implications for research
Many risk factors for fungal infections have beendefined and could
be incorporated into decisions regarding prophylaxis. A more de-
tailed risk assessment associated with cost-effectiveness analyses of
antifungal prophylaxis will further rationalise decisions on anti-
fungal prophylaxis. To that end, studies modelling the risk fac-
tors for IFIs amongst solid organ transplant recipients with exam-
ination of their clinical and economic consequences are required.
Studies of newer antifungal agents or of prophylaxis in other organ
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transplant recipients should be specifically targeted to patients at
increased risk. Such studies should incorporate standardised defi-
nitions of IFIs and basic methodological quality measures.
The potential for selection or generation of resistance to antifungal
agents amongst fungal pathogens remains a major concern associ-
ated with antifungal use. Further study is required to quantify the
occurrence and consequences of such ecological effects before the
prophylactic use of antifungal agents can be more widely recom-
mended.
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C H A R A C T E R I S T I C S O F S T U D I E S




Participants Liver transplant (consecutive patients, at time of transplantation)
131 randomised
2 excluded (pretransplant fungal infection)
Interventions 1. Liposomal amphotericin B 1mg/kg/d IV for 7 days then itraconazole 200mg/d oral for 3 weeks




3. Proven IFI with azole-resistant species
4. Colonisation
5. Colonisation with azole-resistant species
6. Adverse effects
Notes Duration of prophylaxis: 28 days
F/U period: NS
Risk of bias
Bias Authors’ judgement Support for judgement




Participants Renal transplant (within 24 hours post-transplantation)
62 randomised
2 excluded (rejection & nausea)
Interventions 1. Nystatin 1.5MU x5/d oral for 60 days
2. Clotrimazole 10mg tds oral for 60 days
Outcomes 1. SFI
2. Adverse effects
Notes Duration of prophylaxis: 60 days
F/U period: ?60 days
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Gombert 1987 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement




Participants Cardiac transplant (consecutive adult patients, at time of transplantation)
43 randomised
0 excluded




3. Proven IFI with azole-resistant species
4. SFI
5. Adverse effects
Notes Duration of prophylaxis: 1 year
F/U period: 1 year
Risk of bias
Bias Authors’ judgement Support for judgement




Participants Liver transplant (consecutive adult and paediatric patients, at time of transplantation)
143 randomised
0 excluded
Interventions 1. Fluconazole 100mg/d oral for 4 weeks
2. Nystatin 1M qid oral for 4 weeks
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7. Colonisation with azole-resistant species
8. Adverse effects
Notes Duration of prophylaxis: 4 weeks
F/U period: 3 months
Risk of bias
Bias Authors’ judgement Support for judgement









Interventions 1. Fluconazole ?dose oral/iv for 10 weeks plus clotrimazole 100,000U qid oral/nystatin per vagina for 3
months






Notes Duration of prophylaxis: 10 weeks
F/U period: NS
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
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Participants Renal transplant (adults, ?timing post-transplantation)
47 randomised
3 excluded (renal transplant infarction, ?other reasons)
Interventions 1. Clotrimazole 10mg tds oral until steroids tapered to 20mg/d
2. Placebo
Outcomes 1. Proven IFI
2. Proven IFI with azole-resistant species
3. SFI
4. Adverse effects
Notes Duration of prophylaxis: NS
F/U period: NS
Risk of bias
Bias Authors’ judgement Support for judgement




Participants Renal transplant (within 1 week post-transplantation)
110 randomised
16 excluded (side effects, protocol violations, erratic cyclosporin levels, others)
Interventions 1. Ketoconazole 200mg/d oral for 1 year
2. No ketoconazole




Notes Duration of prophylaxis: 1 year
F/U period: 1 year
Risk of bias
Bias Authors’ judgement Support for judgement
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Patton 1994 (Continued)




Participants Liver transplant (aged 3 years or greater, at time of transplantation)
34 randomised
0 excluded
Interventions 1. Nystatin 500,000 U qid oral until hospital discharge
2. Clotrimazole 10mg x5/d oral until hospital discharge
Outcomes 1. SFI
2. Colonisation
Notes Duration of prophylaxis: NS
F/U period: NS
Risk of bias
Bias Authors’ judgement Support for judgement




Participants Liver transplant (consecutive adults, at time of transplantation)
71 randomised
9 excluded (5 “retracted consent”, 2 transplant cancelled, 1 “protocol violation”, 1 “lost consent”)






Notes Duration of prophylaxis: 8 weeks
F/U period: NS
Risk of bias
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Sharpe 2003 (Continued)
Bias Authors’ judgement Support for judgement




Participants Renal transplant (?timing post-transplantation)
100 randomised
0 excluded




Notes Duration of prophylaxis: 1 year
F/U period: 1 year
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Unclear risk B - Unclear
Tollemar 1995
Methods Country: Sweden & Finland
Setting: 2 hospitals
Participants Liver transplant (consecutive adults and children, at time of transplantation)
86 randomised
9 excluded (4 suspected FI, 3 intercurrent complications, 1 no preop data, 1 intraop death)




3. Proven with azole-resistant species
4. Suspected IFI
5. Adverse effects
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Tollemar 1995 (Continued)
Notes Duration of prophylaxis: 5 days
F/U period: 30 days and 1 year
Risk of bias
Bias Authors’ judgement Support for judgement




Participants Liver transplant (consecutive adults and children, at time of transplantation)
75 randomised
3 excluded (2 deaths within 9 days, 1 IFI)
Interventions 1. Fluconazole 100mg/d oral/iv for 4 weeks
2. Amphotericin B 1500mg qid oral for 4 weeks
Outcomes 1. Mortality
2. Proven IFI
3. Proven IFI with azole-resistant species
4. Colonisation
5. Colonisation with azole-resistant species
6. Adverse effects
Notes Duration of prophyalxis: 4 weeks
F/U period: 8 weeks
Risk of bias
Bias Authors’ judgement Support for judgement




Participants Liver transplant (consecutive adults, at time of transplantation)
236 randomised
24 excluded (18 transplant cancelled/intraop death, 1 pregnant, 1 child, 1 dialysis, 1 baseline IFI, 2
retransplant)
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Winston 1999 (Continued)








7. Colonisation with azole-resistant species
8. Adverse effects
Notes Duration of prophylaxis: 10 weeks
F/U period: NS (?10 weeks)
Risk of bias
Bias Authors’ judgement Support for judgement




Participants Liver transplant (consecutive adults, at time of transplantation)
204 randomised
16 excluded (14 transplant cancelled/intraop death, 1 baseline suspected IFI, 1 islet cell transplant)
Interventions 1. Itraconazole 200mg bd oral for 10 weeks
2. Fluconazole 400mg/d iv then oral for 10 weeks
Outcomes 1. Mortality
2. Proven IFI




7. Colonisation with azole-resistant species
8. Adverse events
Notes Duration of prophylaxis: 10 weeks
F/U period: 1 year
Risk of bias
Bias Authors’ judgement Support for judgement
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Winston 2002 (Continued)
Allocation concealment? Unclear risk B - Unclear
IFI = invasive fungal infection; SFI = superficial fungal infection
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D A T A A N D A N A L Y S E S
Comparison 1. Systemic antifungal agent versus placebo/no antifungal/nonabsorbable antifungal agent




participants Statistical method Effect size
1 Mortality 9 889 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.57, 1.44]
1.1 Fluconazole 4 477 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.53, 1.82]
1.2 Itraconazole 2 191 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.18, 1.85]
1.3 Liposomal amphotericin
B
1 84 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.15, 2.24]
1.4 Ketoconazole 2 137 Risk Ratio (M-H, Random, 95% CI) 1.50 [0.18, 12.87]
2 Proven invasive fungal infection 9 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Fluconazole 4 477 Risk Ratio (M-H, Random, 95% CI) 0.28 [0.13, 0.57]
2.2 Itraconazole 2 191 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.44, 1.45]
2.3 Liposomal amphotericin
B
1 84 Risk Ratio (M-H, Random, 95% CI) 0.07 [0.00, 1.26]
2.4 Ketoconazole 2 137 Risk Ratio (M-H, Random, 95% CI) 1.30 [0.08, 20.41]
3 Proven invasive fungal infection
(azole-resistant Candida
species)
6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Fluconazole 3 430 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.14, 2.36]
3.2 Itraconazole 1 129 Risk Ratio (M-H, Random, 95% CI) 3.66 [0.19, 69.37]
3.3 Liposomal amphotericin
B
1 84 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.4 Ketoconazole 1 43 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Proven invasive fungal infection
(moulds)
6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Fluconazole 3 430 Risk Ratio (M-H, Random, 95% CI) 0.47 [0.11, 1.92]
4.2 Itraconazole 1 129 Risk Ratio (M-H, Random, 95% CI) 2.62 [0.13, 53.34]
4.3 Liposomal amphotericin
B
1 84 Risk Ratio (M-H, Random, 95% CI) 0.32 [0.01, 7.59]
4.4 Ketoconazole 1 43 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.11, 3.13]
5 Proven invasive fungal infection
(azole-resistant Candida species
or moulds)
6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Fluconazole 3 430 Risk Ratio (M-H, Random, 95% CI) 0.50 [0.19, 1.33]
5.2 Itraconazole 1 129 Risk Ratio (M-H, Random, 95% CI) 5.76 [0.33, 101.77]
5.3 Liposomal amphotericin
B
1 84 Risk Ratio (M-H, Random, 95% CI) 0.32 [0.01, 7.59]
5.4 Ketoconazole 1 43 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.11, 3.13]
6 Suspected invasive fungal
infection
6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Fluconazole 4 477 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.48, 2.34]
6.2 Itraconazole 1 62 Risk Ratio (M-H, Random, 95% CI) 0.25 [0.03, 1.93]
6.3 Liposomal amphotericin
B
1 84 Risk Ratio (M-H, Random, 95% CI) 1.27 [0.30, 5.34]
6.4 Ketoconazole 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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7 Proven or suspected invasive
fungal infection
6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 Fluconazole 4 477 Risk Ratio (M-H, Random, 95% CI) 0.46 [0.28, 0.76]
7.2 Itraconazole 1 62 Risk Ratio (M-H, Random, 95% CI) 0.25 [0.03, 1.93]
7.3 Liposomal amphotericin
B
1 84 Risk Ratio (M-H, Random, 95% CI) 0.42 [0.14, 1.27]
7.4 Ketoconazole 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8 Superficial fungal infection 7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 Fluconazole 3 402 Risk Ratio (M-H, Random, 95% CI) 0.24 [0.10, 0.59]
8.2 Itraconazole 1 62 Risk Ratio (M-H, Random, 95% CI) 0.21 [0.01, 3.87]
8.3 Liposomal amphotericin
B
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.4 Ketoconazole 3 237 Risk Ratio (M-H, Random, 95% CI) 0.17 [0.06, 0.51]
9 Fungal colonisation 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 Fluconazole 3 360 Risk Ratio (M-H, Random, 95% CI) 0.47 [0.37, 0.61]
9.2 Itraconazole 1 129 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.41, 0.80]
9.3 Liposomal amphotericin
B
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]




4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
10.1 Fluconazole 3 360 Risk Ratio (M-H, Random, 95% CI) 1.82 [0.66, 5.03]
10.2 Itraconazole 1 129 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.20, 5.43]
10.3 Liposomal amphotericin
B
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.4 Ketoconazole 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11 Adverse effects requiring
cessation
9 Risk Ratio (M-H, Random, 95% CI) Subtotals only
11.1 Fluconazole 4 474 Risk Ratio (M-H, Random, 95% CI) 1.17 [0.65, 2.10]
11.2 Itraconazole 1 127 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11.3 Liposomal amphotericin
B
1 84 Risk Ratio (M-H, Random, 95% CI) 1.91 [0.18, 20.24]
11.4 Ketoconazole 3 237 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. Systemic antifungal agent versus another systemic antifungal agent




participants Statistical method Effect size
1 Mortality 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Itraconazole versus
fluconazole




1 85 Risk Ratio (M-H, Random, 95% CI) 1.54 [0.27, 8.73]
2 Proven invasive fungal infection 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Itraconazole versus
fluconazole
1 188 Risk Ratio (M-H, Random, 95% CI) 2.19 [0.58, 8.21]
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1 85 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.48, 2.20]
3 Proven invasive fungal infection
(azole-resistant Candida
species)
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Itraconazole versus
fluconazole




1 85 Risk Ratio (M-H, Random, 95% CI) 2.05 [0.19, 21.74]
4 Proven invasive fungal infection
(moulds)
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
4.1 Itraconazole versus
fluconazole




0 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5 Proven invasive fungal infection
(moulds or azole-resistant
Candida species)
2 Risk Ratio (M-H, Random, 95% CI) Totals not selected
5.1 Itraconazole versus
fluconazole




1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6 Suspected invasive fungal
infection
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
6.1 Itraconazole versus
fluconazole




0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Proven or suspected invasive
fungal infection
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
7.1 Itraconazole versus
fluconazole




0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Superficial fungal infection 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
8.1 Itraconazole versus
fluconazole




0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9 Fungal colonisation 2 Risk Ratio (M-H, Random, 95% CI) Totals not selected
9.1 Itraconazole versus
fluconazole
1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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2 Risk Ratio (M-H, Random, 95% CI) Totals not selected
10.1 Itraconazole versus
fluconazole




1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11 Adverse effects requiring
cessation
2 Risk Ratio (M-H, Random, 95% CI) Totals not selected
11.1 Itraconazole versus
fluconazole




1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 3. Nonabsorbable antifungal agent versus no antifungal agent




participants Statistical method Effect size
1 Mortality 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2 Proven invasive fungal infection 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2.1 Clotrimazole 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Proven invasive fungal infections
(azole-resistant Candida
species)
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3.1 Clotrimazole 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Proven invasive fungal infection
(moulds)
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
4.1 Clotrimazole 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5 Proven invasive fungal infection
(azole-resistant Candida species
and moulds)
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
5.1 Clotrimazole 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6 Suspected invasive fungal
infection
0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7 Proven or suspected invasive
fungal infection
0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8 Superficial fungal infection 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
8.1 Clotrimazole 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9 Fungal colonisation 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
10 Fungal colonisation (azole-
resistant Candida species)
0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
11 Adverse effects requiring
cessation
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
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11.1 Clotrimazole 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 4. Nonabsorbable antifungal agent versus another nonabsorbable antifungal agent




participants Statistical method Effect size
1 Mortality 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2 Proven invasive fungal infection 0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3 Proven invasive fungal infections
(azole-resistant Candida
species)
0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4 Proven invasive fungal infections
(moulds)
0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5 Proven invasive fungal infection
(azole-resistant Candida species
or moulds)
0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6 Suspected invasive fungal
infection
0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7 Proven or suspected invasive
fungal infection
0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8 Superficial fungal infection 2 Risk Ratio (M-H, Random, 95% CI) Totals not selected
8.1 Nystatin versus
clotrimazole
2 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9 Fungal colonisation 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
9.1 Nystatin versus
clotrimazole
1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10 Fungal colonisation (azole-
resistant Candida species)
0 Risk Ratio (M-H, Random, 95% CI) Subtotals only
11 Adverse effects requiring
cessation
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
11.1 Nystatin versus nystatin 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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Analysis 1.1. Comparison 1 Systemic antifungal agent versus placebo/no antifungal/nonabsorbable
antifungal agent, Outcome 1 Mortality.
Review: Antifungal agents for preventing fungal infections in solid organ transplant recipients
Comparison: 1 Systemic antifungal agent versus placebo/no antifungal/nonabsorbable antifungal agent
Outcome: 1 Mortality









Lumbreras 1996 10/76 9/67 23.3 % 0.98 [ 0.42, 2.27 ]
Meyers 1997 6/23 2/24 8.8 % 3.13 [ 0.70, 13.95 ]
Tortorano 1995 0/38 2/37 2.3 % 0.19 [ 0.01, 3.93 ]
Winston 1999 12/108 15/104 29.7 % 0.77 [ 0.38, 1.57 ]
Subtotal (95% CI) 245 232 64.2 % 0.98 [ 0.53, 1.82 ]
Total events: 28 (Antifungal), 28 (Control)
Heterogeneity: Tau2 = 0.09; Chi2 = 3.85, df = 3 (P = 0.28); I2 =22%
Test for overall effect: Z = 0.07 (P = 0.94)
2 Itraconazole
Biancofiore 2002 5/85 3/44 10.1 % 0.86 [ 0.22, 3.44 ]
Sharpe 2003 1/25 6/37 4.9 % 0.25 [ 0.03, 1.93 ]
Subtotal (95% CI) 110 81 14.9 % 0.58 [ 0.18, 1.85 ]
Total events: 6 (Antifungal), 9 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 1.02, df = 1 (P = 0.31); I2 =1%
Test for overall effect: Z = 0.92 (P = 0.36)
3 Liposomal amphotericin B
Tollemar 1995 3/43 5/41 10.3 % 0.57 [ 0.15, 2.24 ]
Subtotal (95% CI) 43 41 10.3 % 0.57 [ 0.15, 2.24 ]
Total events: 3 (Antifungal), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
4 Ketoconazole
Keogh 1995 1/23 2/20 3.8 % 0.43 [ 0.04, 4.44 ]
Patton 1994 3/26 2/68 6.7 % 3.92 [ 0.69, 22.15 ]
Subtotal (95% CI) 49 88 10.5 % 1.50 [ 0.18, 12.87 ]
Total events: 4 (Antifungal), 4 (Control)
Heterogeneity: Tau2 = 1.35; Chi2 = 2.23, df = 1 (P = 0.14); I2 =55%
Test for overall effect: Z = 0.37 (P = 0.71)
Total (95% CI) 447 442 100.0 % 0.90 [ 0.57, 1.44 ]
Total events: 41 (Antifungal), 46 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 9.01, df = 8 (P = 0.34); I2 =11%
Test for overall effect: Z = 0.43 (P = 0.67)
0.01 0.1 1 10 100
Favours antifungal Favours control
30Antifungal agents for preventing fungal infections in solid organ transplant recipients (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.2. Comparison 1 Systemic antifungal agent versus placebo/no antifungal/nonabsorbable
antifungal agent, Outcome 2 Proven invasive fungal infection.
Review: Antifungal agents for preventing fungal infections in solid organ transplant recipients
Comparison: 1 Systemic antifungal agent versus placebo/no antifungal/nonabsorbable antifungal agent
Outcome: 2 Proven invasive fungal infection









Lumbreras 1996 2/76 3/67 24.6 % 0.59 [ 0.10, 3.41 ]
Meyers 1997 0/23 1/24 9.5 % 0.35 [ 0.01, 8.11 ]
Tortorano 1995 0/38 3/37 10.8 % 0.14 [ 0.01, 2.60 ]
Winston 1999 6/108 24/104 55.2 % 0.24 [ 0.10, 0.57 ]
Subtotal (95% CI) 245 232 100.0 % 0.28 [ 0.13, 0.57 ]
Total events: 8 (Antifungal), 31 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.04, df = 3 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 3.49 (P = 0.00048)
2 Itraconazole
Biancofiore 2002 20/85 13/44 100.0 % 0.80 [ 0.44, 1.45 ]
Sharpe 2003 0/25 0/37 Not estimable
Subtotal (95% CI) 110 81 100.0 % 0.80 [ 0.44, 1.45 ]
Total events: 20 (Antifungal), 13 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
3 Liposomal amphotericin B
Tollemar 1995 0/43 6/41 100.0 % 0.07 [ 0.00, 1.26 ]
Subtotal (95% CI) 43 41 100.0 % 0.07 [ 0.00, 1.26 ]
Total events: 0 (Antifungal), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.80 (P = 0.072)
4 Ketoconazole
Keogh 1995 2/23 4/20 75.2 % 0.43 [ 0.09, 2.13 ]
Patton 1994 1/26 0/68 24.8 % 7.67 [ 0.32, 182.44 ]
Subtotal (95% CI) 49 88 100.0 % 1.30 [ 0.08, 20.41 ]
Total events: 3 (Antifungal), 4 (Control)
Heterogeneity: Tau2 = 2.53; Chi2 = 2.55, df = 1 (P = 0.11); I2 =61%
Test for overall effect: Z = 0.19 (P = 0.85)
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Analysis 1.3. Comparison 1 Systemic antifungal agent versus placebo/no antifungal/nonabsorbable
antifungal agent, Outcome 3 Proven invasive fungal infection (azole-resistant Candida species).
Review: Antifungal agents for preventing fungal infections in solid organ transplant recipients
Comparison: 1 Systemic antifungal agent versus placebo/no antifungal/nonabsorbable antifungal agent
Outcome: 3 Proven invasive fungal infection (azole-resistant Candida species)









Lumbreras 1996 0/76 0/67 Not estimable
Tortorano 1995 0/38 0/37 Not estimable
Winston 1999 3/108 5/104 100.0 % 0.58 [ 0.14, 2.36 ]
Subtotal (95% CI) 222 208 100.0 % 0.58 [ 0.14, 2.36 ]
Total events: 3 (Antifungal), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.44)
2 Itraconazole
Biancofiore 2002 3/85 0/44 100.0 % 3.66 [ 0.19, 69.37 ]
Subtotal (95% CI) 85 44 100.0 % 3.66 [ 0.19, 69.37 ]
Total events: 3 (Antifungal), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.39)
3 Liposomal amphotericin B
Tollemar 1995 0/43 0/41 Not estimable
Subtotal (95% CI) 43 41 Not estimable
Total events: 0 (Antifungal), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Ketoconazole
Keogh 1995 0/23 0/20 Not estimable
Subtotal (95% CI) 23 20 Not estimable
Total events: 0 (Antifungal), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.4. Comparison 1 Systemic antifungal agent versus placebo/no antifungal/nonabsorbable
antifungal agent, Outcome 4 Proven invasive fungal infection (moulds).
Review: Antifungal agents for preventing fungal infections in solid organ transplant recipients
Comparison: 1 Systemic antifungal agent versus placebo/no antifungal/nonabsorbable antifungal agent
Outcome: 4 Proven invasive fungal infection (moulds)









Lumbreras 1996 2/76 1/67 35.4 % 1.76 [ 0.16, 19.01 ]
Tortorano 1995 0/38 2/37 22.2 % 0.19 [ 0.01, 3.93 ]
Winston 1999 1/108 4/104 42.4 % 0.24 [ 0.03, 2.12 ]
Subtotal (95% CI) 222 208 100.0 % 0.47 [ 0.11, 1.92 ]
Total events: 3 (Antifungal), 7 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.89, df = 2 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 1.06 (P = 0.29)
2 Itraconazole
Biancofiore 2002 2/85 0/44 100.0 % 2.62 [ 0.13, 53.34 ]
Subtotal (95% CI) 85 44 100.0 % 2.62 [ 0.13, 53.34 ]
Total events: 2 (Antifungal), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
3 Liposomal amphotericin B
Tollemar 1995 0/43 1/41 100.0 % 0.32 [ 0.01, 7.59 ]
Subtotal (95% CI) 43 41 100.0 % 0.32 [ 0.01, 7.59 ]
Total events: 0 (Antifungal), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
4 Ketoconazole
Keogh 1995 2/23 3/20 100.0 % 0.58 [ 0.11, 3.13 ]
Subtotal (95% CI) 23 20 100.0 % 0.58 [ 0.11, 3.13 ]
Total events: 2 (Antifungal), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
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Analysis 1.5. Comparison 1 Systemic antifungal agent versus placebo/no antifungal/nonabsorbable
antifungal agent, Outcome 5 Proven invasive fungal infection (azole-resistant Candida species or moulds).
Review: Antifungal agents for preventing fungal infections in solid organ transplant recipients
Comparison: 1 Systemic antifungal agent versus placebo/no antifungal/nonabsorbable antifungal agent
Outcome: 5 Proven invasive fungal infection (azole-resistant Candida species or moulds)









Lumbreras 1996 2/76 1/67 16.9 % 1.76 [ 0.16, 19.01 ]
Tortorano 1995 0/38 2/37 10.6 % 0.19 [ 0.01, 3.93 ]
Winston 1999 4/108 9/104 72.6 % 0.43 [ 0.14, 1.35 ]
Subtotal (95% CI) 222 208 100.0 % 0.50 [ 0.19, 1.33 ]
Total events: 6 (Antifungal), 12 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.53, df = 2 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.39 (P = 0.16)
2 Itraconazole
Biancofiore 2002 5/85 0/44 100.0 % 5.76 [ 0.33, 101.77 ]
Subtotal (95% CI) 85 44 100.0 % 5.76 [ 0.33, 101.77 ]
Total events: 5 (Antifungal), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
3 Liposomal amphotericin B
Tollemar 1995 0/43 1/41 100.0 % 0.32 [ 0.01, 7.59 ]
Subtotal (95% CI) 43 41 100.0 % 0.32 [ 0.01, 7.59 ]
Total events: 0 (Antifungal), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
4 Ketoconazole
Keogh 1995 2/23 3/20 100.0 % 0.58 [ 0.11, 3.13 ]
Subtotal (95% CI) 23 20 100.0 % 0.58 [ 0.11, 3.13 ]
Total events: 2 (Antifungal), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
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Analysis 1.6. Comparison 1 Systemic antifungal agent versus placebo/no antifungal/nonabsorbable
antifungal agent, Outcome 6 Suspected invasive fungal infection.
Review: Antifungal agents for preventing fungal infections in solid organ transplant recipients
Comparison: 1 Systemic antifungal agent versus placebo/no antifungal/nonabsorbable antifungal agent
Outcome: 6 Suspected invasive fungal infection









Tortorano 1995 4/38 3/37 31.0 % 1.30 [ 0.31, 5.41 ]
Lumbreras 1996 2/76 2/67 16.9 % 0.88 [ 0.13, 6.09 ]
Meyers 1997 2/23 2/24 18.0 % 1.04 [ 0.16, 6.80 ]
Winston 1999 4/108 4/104 34.1 % 0.96 [ 0.25, 3.75 ]
Subtotal (95% CI) 245 232 100.0 % 1.06 [ 0.48, 2.34 ]
Total events: 12 (Antifungal), 11 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.13, df = 3 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.89)
2 Itraconazole
Sharpe 2003 1/25 6/37 100.0 % 0.25 [ 0.03, 1.93 ]
Subtotal (95% CI) 25 37 100.0 % 0.25 [ 0.03, 1.93 ]
Total events: 1 (Antifungal), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
3 Liposomal amphotericin B
Tollemar 1995 4/43 3/41 100.0 % 1.27 [ 0.30, 5.34 ]
Subtotal (95% CI) 43 41 100.0 % 1.27 [ 0.30, 5.34 ]
Total events: 4 (Antifungal), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
4 Ketoconazole
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Antifungal), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.7. Comparison 1 Systemic antifungal agent versus placebo/no antifungal/nonabsorbable
antifungal agent, Outcome 7 Proven or suspected invasive fungal infection.
Review: Antifungal agents for preventing fungal infections in solid organ transplant recipients
Comparison: 1 Systemic antifungal agent versus placebo/no antifungal/nonabsorbable antifungal agent
Outcome: 7 Proven or suspected invasive fungal infection









Lumbreras 1996 4/76 5/67 15.8 % 0.71 [ 0.20, 2.52 ]
Meyers 1997 2/23 3/24 8.9 % 0.70 [ 0.13, 3.79 ]
Tortorano 1995 4/38 6/37 18.3 % 0.65 [ 0.20, 2.12 ]
Winston 1999 10/108 28/104 57.0 % 0.34 [ 0.18, 0.67 ]
Subtotal (95% CI) 245 232 100.0 % 0.46 [ 0.28, 0.76 ]
Total events: 20 (Antifungal), 42 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.71, df = 3 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 3.00 (P = 0.0027)
2 Itraconazole
Sharpe 2003 1/25 6/37 100.0 % 0.25 [ 0.03, 1.93 ]
Subtotal (95% CI) 25 37 100.0 % 0.25 [ 0.03, 1.93 ]
Total events: 1 (Antifungal), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
3 Liposomal amphotericin B
Tollemar 1995 4/43 9/41 100.0 % 0.42 [ 0.14, 1.27 ]
Subtotal (95% CI) 43 41 100.0 % 0.42 [ 0.14, 1.27 ]
Total events: 4 (Antifungal), 9 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
4 Ketoconazole
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Antifungal), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.8. Comparison 1 Systemic antifungal agent versus placebo/no antifungal/nonabsorbable
antifungal agent, Outcome 8 Superficial fungal infection.
Review: Antifungal agents for preventing fungal infections in solid organ transplant recipients
Comparison: 1 Systemic antifungal agent versus placebo/no antifungal/nonabsorbable antifungal agent
Outcome: 8 Superficial fungal infection









Lumbreras 1996 10/76 21/67 52.8 % 0.42 [ 0.21, 0.83 ]
Meyers 1997 1/23 6/24 12.1 % 0.17 [ 0.02, 1.34 ]
Winston 1999 4/108 29/104 35.0 % 0.13 [ 0.05, 0.36 ]
Subtotal (95% CI) 207 195 100.0 % 0.24 [ 0.10, 0.59 ]
Total events: 15 (Antifungal), 56 (Control)
Heterogeneity: Tau2 = 0.29; Chi2 = 3.90, df = 2 (P = 0.14); I2 =49%
Test for overall effect: Z = 3.15 (P = 0.0016)
2 Itraconazole
Sharpe 2003 0/25 3/37 100.0 % 0.21 [ 0.01, 3.87 ]
Subtotal (95% CI) 25 37 100.0 % 0.21 [ 0.01, 3.87 ]
Total events: 0 (Antifungal), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
3 Liposomal amphotericin B
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Antifungal), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Ketoconazole
Keogh 1995 0/23 4/20 11.2 % 0.10 [ 0.01, 1.70 ]
Patton 1994 2/26 12/68 36.8 % 0.44 [ 0.10, 1.82 ]
Sobh 1995 3/51 31/49 52.1 % 0.09 [ 0.03, 0.28 ]
Subtotal (95% CI) 100 137 100.0 % 0.17 [ 0.06, 0.51 ]
Total events: 5 (Antifungal), 47 (Control)
Heterogeneity: Tau2 = 0.32; Chi2 = 2.96, df = 2 (P = 0.23); I2 =32%
Test for overall effect: Z = 3.17 (P = 0.0015)
0.005 0.1 1 10 200
Favours antifungal Favours control
37Antifungal agents for preventing fungal infections in solid organ transplant recipients (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.9. Comparison 1 Systemic antifungal agent versus placebo/no antifungal/nonabsorbable
antifungal agent, Outcome 9 Fungal colonisation.
Review: Antifungal agents for preventing fungal infections in solid organ transplant recipients
Comparison: 1 Systemic antifungal agent versus placebo/no antifungal/nonabsorbable antifungal agent
Outcome: 9 Fungal colonisation









Lumbreras 1996 19/76 35/67 30.2 % 0.48 [ 0.30, 0.75 ]
Tortorano 1995 9/38 11/34 11.0 % 0.73 [ 0.35, 1.55 ]
Winston 1999 29/85 47/60 58.8 % 0.44 [ 0.32, 0.60 ]
Subtotal (95% CI) 199 161 100.0 % 0.47 [ 0.37, 0.61 ]
Total events: 57 (Antifungal), 93 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.58, df = 2 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 5.88 (P < 0.00001)
2 Itraconazole
Biancofiore 2002 33/85 30/44 100.0 % 0.57 [ 0.41, 0.80 ]
Subtotal (95% CI) 85 44 100.0 % 0.57 [ 0.41, 0.80 ]
Total events: 33 (Antifungal), 30 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.30 (P = 0.00097)
3 Liposomal amphotericin B
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Antifungal), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Ketoconazole
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Antifungal), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.2 0.5 1 2 5
Favours antifungal Favours control
38Antifungal agents for preventing fungal infections in solid organ transplant recipients (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.10. Comparison 1 Systemic antifungal agent versus placebo/no antifungal/nonabsorbable
antifungal agent, Outcome 10 Fungal colonisation (azole-resistant Candida species).
Review: Antifungal agents for preventing fungal infections in solid organ transplant recipients
Comparison: 1 Systemic antifungal agent versus placebo/no antifungal/nonabsorbable antifungal agent
Outcome: 10 Fungal colonisation (azole-resistant Candida species)









Lumbreras 1996 5/76 4/67 30.6 % 1.10 [ 0.31, 3.94 ]
Tortorano 1995 9/38 0/34 7.6 % 17.05 [ 1.03, 282.36 ]
Winston 1999 18/85 8/60 61.8 % 1.59 [ 0.74, 3.41 ]
Subtotal (95% CI) 199 161 100.0 % 1.82 [ 0.66, 5.03 ]
Total events: 32 (Antifungal), 12 (Control)
Heterogeneity: Tau2 = 0.35; Chi2 = 3.46, df = 2 (P = 0.18); I2 =42%
Test for overall effect: Z = 1.16 (P = 0.25)
2 Itraconazole
Biancofiore 2002 4/85 2/44 100.0 % 1.04 [ 0.20, 5.43 ]
Subtotal (95% CI) 85 44 100.0 % 1.04 [ 0.20, 5.43 ]
Total events: 4 (Antifungal), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
3 Liposomal amphotericin B
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Antifungal), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Ketoconazole
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Antifungal), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.11. Comparison 1 Systemic antifungal agent versus placebo/no antifungal/nonabsorbable
antifungal agent, Outcome 11 Adverse effects requiring cessation.
Review: Antifungal agents for preventing fungal infections in solid organ transplant recipients
Comparison: 1 Systemic antifungal agent versus placebo/no antifungal/nonabsorbable antifungal agent
Outcome: 11 Adverse effects requiring cessation









Lumbreras 1996 1/76 0/67 3.3 % 2.65 [ 0.11, 63.96 ]
Meyers 1997 12/23 10/24 89.9 % 1.25 [ 0.68, 2.31 ]
Tortorano 1995 0/38 0/34 Not estimable
Winston 1999 1/108 3/104 6.7 % 0.32 [ 0.03, 3.04 ]
Subtotal (95% CI) 245 229 100.0 % 1.17 [ 0.65, 2.10 ]
Total events: 14 (Antifungal), 13 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.62, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.53 (P = 0.59)
2 Itraconazole
Biancofiore 2002 0/85 0/42 Not estimable
Subtotal (95% CI) 85 42 Not estimable
Total events: 0 (Antifungal), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Liposomal amphotericin B
Tollemar 1995 2/43 1/41 100.0 % 1.91 [ 0.18, 20.24 ]
Subtotal (95% CI) 43 41 100.0 % 1.91 [ 0.18, 20.24 ]
Total events: 2 (Antifungal), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
4 Ketoconazole
Keogh 1995 0/23 0/20 Not estimable
Patton 1994 0/26 0/68 Not estimable
Sobh 1995 0/51 0/49 Not estimable
Subtotal (95% CI) 100 137 Not estimable
Total events: 0 (Antifungal), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 2.1. Comparison 2 Systemic antifungal agent versus another systemic antifungal agent, Outcome 1
Mortality.
Review: Antifungal agents for preventing fungal infections in solid organ transplant recipients
Comparison: 2 Systemic antifungal agent versus another systemic antifungal agent
Outcome: 1 Mortality








1 Itraconazole versus fluconazole
Winston 2002 12/97 7/91 100.0 % 1.61 [ 0.66, 3.91 ]
Subtotal (95% CI) 97 91 100.0 % 1.61 [ 0.66, 3.91 ]
Total events: 12 (Intervention 1), 7 (Intervention 2)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
2 Liposomal amphotericin/itraconazole versus Fluconazole/itraconazole
Biancofiore 2002 3/42 2/43 100.0 % 1.54 [ 0.27, 8.73 ]
Subtotal (95% CI) 42 43 100.0 % 1.54 [ 0.27, 8.73 ]
Total events: 3 (Intervention 1), 2 (Intervention 2)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
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Analysis 2.2. Comparison 2 Systemic antifungal agent versus another systemic antifungal agent, Outcome 2
Proven invasive fungal infection.
Review: Antifungal agents for preventing fungal infections in solid organ transplant recipients
Comparison: 2 Systemic antifungal agent versus another systemic antifungal agent
Outcome: 2 Proven invasive fungal infection








1 Itraconazole versus fluconazole
Winston 2002 7/97 3/91 100.0 % 2.19 [ 0.58, 8.21 ]
Subtotal (95% CI) 97 91 100.0 % 2.19 [ 0.58, 8.21 ]
Total events: 7 (Intervention 1), 3 (Intervention 2)
Heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.25)
2 Liposomal amphotericin/itraconazole versus Fluconazole/itraconazole
Biancofiore 2002 10/42 10/43 100.0 % 1.02 [ 0.48, 2.20 ]
Subtotal (95% CI) 42 43 100.0 % 1.02 [ 0.48, 2.20 ]
Total events: 10 (Intervention 1), 10 (Intervention 2)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
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Analysis 2.3. Comparison 2 Systemic antifungal agent versus another systemic antifungal agent, Outcome 3
Proven invasive fungal infection (azole-resistant Candida species).
Review: Antifungal agents for preventing fungal infections in solid organ transplant recipients
Comparison: 2 Systemic antifungal agent versus another systemic antifungal agent
Outcome: 3 Proven invasive fungal infection (azole-resistant Candida species)








1 Itraconazole versus fluconazole
Winston 2002 4/97 2/91 100.0 % 1.88 [ 0.35, 10.00 ]
Subtotal (95% CI) 97 91 100.0 % 1.88 [ 0.35, 10.00 ]
Total events: 4 (Intervention 1), 2 (Intervention 2)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
2 Liposomal amphotericin/itraconazole versus Fluconazole/itraconazole
Biancofiore 2002 2/42 1/43 100.0 % 2.05 [ 0.19, 21.74 ]
Subtotal (95% CI) 42 43 100.0 % 2.05 [ 0.19, 21.74 ]
Total events: 2 (Intervention 1), 1 (Intervention 2)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
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Analysis 2.4. Comparison 2 Systemic antifungal agent versus another systemic antifungal agent, Outcome 4
Proven invasive fungal infection (moulds).
Review: Antifungal agents for preventing fungal infections in solid organ transplant recipients
Comparison: 2 Systemic antifungal agent versus another systemic antifungal agent
Outcome: 4 Proven invasive fungal infection (moulds)








1 Itraconazole versus fluconazole
Winston 2002 2/97 1/91 1.89 [ 0.17, 21.26 ]
2 Liposomal amphotericin/itraconazole versus Fluconazole/itraconazole
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Analysis 2.5. Comparison 2 Systemic antifungal agent versus another systemic antifungal agent, Outcome 5
Proven invasive fungal infection (moulds or azole-resistant Candida species).
Review: Antifungal agents for preventing fungal infections in solid organ transplant recipients
Comparison: 2 Systemic antifungal agent versus another systemic antifungal agent
Outcome: 5 Proven invasive fungal infection (moulds or azole-resistant Candida species)








1 Itraconazole versus fluconazole
Winston 2002 6/97 3/91 1.88 [ 0.48, 7.28 ]
2 Liposomal amphotericin/itraconazole versus Fluconazole/itraconazole
Biancofiore 2002 3/42 3/42 1.00 [ 0.21, 4.67 ]
0.1 0.2 0.5 1 2 5 10
Favours interventn 1 Favours interventn 2
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Analysis 2.6. Comparison 2 Systemic antifungal agent versus another systemic antifungal agent, Outcome 6
Suspected invasive fungal infection.
Review: Antifungal agents for preventing fungal infections in solid organ transplant recipients
Comparison: 2 Systemic antifungal agent versus another systemic antifungal agent
Outcome: 6 Suspected invasive fungal infection








1 Itraconazole versus fluconazole
Winston 2002 0/97 3/91 0.13 [ 0.01, 2.56 ]
2 Liposomal amphotericin/itraconazole versus Fluconazole/itraconazole
0.005 0.1 1 10 200
Favours interventn 1 Favours interventn 2
Analysis 2.7. Comparison 2 Systemic antifungal agent versus another systemic antifungal agent, Outcome 7
Proven or suspected invasive fungal infection.
Review: Antifungal agents for preventing fungal infections in solid organ transplant recipients
Comparison: 2 Systemic antifungal agent versus another systemic antifungal agent
Outcome: 7 Proven or suspected invasive fungal infection
Study or subgroup Intervention 1 Intervention 2 Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Itraconazole versus fluconazole
Winston 2002 7/97 6/91 1.10 [ 0.36, 3.41 ]
2 Liposomal amphotericin/itraconazole versus Fluconazole/itraconazole
0.2 0.5 1 2 5
Favours interventn 1 Favours interventn 2
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Analysis 2.8. Comparison 2 Systemic antifungal agent versus another systemic antifungal agent, Outcome 8
Superficial fungal infection.
Review: Antifungal agents for preventing fungal infections in solid organ transplant recipients
Comparison: 2 Systemic antifungal agent versus another systemic antifungal agent
Outcome: 8 Superficial fungal infection








1 Itraconazole versus fluconazole
Winston 2002 2/97 1/91 1.88 [ 0.17, 20.34 ]
2 Liposomal amphotericin/itraconazole versus Fluconazole/itraconazole
0.02 0.1 1 10 50
Favours interventn 1 Favours interventn 2
Analysis 2.9. Comparison 2 Systemic antifungal agent versus another systemic antifungal agent, Outcome 9
Fungal colonisation.
Review: Antifungal agents for preventing fungal infections in solid organ transplant recipients
Comparison: 2 Systemic antifungal agent versus another systemic antifungal agent
Outcome: 9 Fungal colonisation








1 Itraconazole versus fluconazole
Winston 2002 29/87 24/79 1.10 [ 0.70, 1.72 ]
2 Liposomal amphotericin/itraconazole versus Fluconazole/itraconazole
Biancofiore 2002 15/42 18/43 0.85 [ 0.50, 1.46 ]
0.5 0.7 1 1.5 2
Favours interventn 1 Favours interventn 2
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Analysis 2.10. Comparison 2 Systemic antifungal agent versus another systemic antifungal agent, Outcome
10 Fungal colonisation (azole-resistant Candida species).
Review: Antifungal agents for preventing fungal infections in solid organ transplant recipients
Comparison: 2 Systemic antifungal agent versus another systemic antifungal agent
Outcome: 10 Fungal colonisation (azole-resistant Candida species)








1 Itraconazole versus fluconazole
Winston 2002 21/87 17/79 1.12 [ 0.64, 1.97 ]
2 Liposomal amphotericin/itraconazole versus Fluconazole/itraconazole
Biancofiore 2002 1/42 3/43 0.34 [ 0.04, 3.15 ]
0.02 0.1 1 10 50
Favours interventn 1 Favours interventn 2
Analysis 2.11. Comparison 2 Systemic antifungal agent versus another systemic antifungal agent, Outcome
11 Adverse effects requiring cessation.
Review: Antifungal agents for preventing fungal infections in solid organ transplant recipients
Comparison: 2 Systemic antifungal agent versus another systemic antifungal agent
Outcome: 11 Adverse effects requiring cessation








1 Itraconazole versus fluconazole
Winston 2002 0/97 0/91 Not estimable
2 Liposomal amphotericin/itraconazole versus Fluconazole/itraconazole
Biancofiore 2002 0/42 0/43 Not estimable
0.1 0.2 0.5 1 2 5 10
Favours interventn 1 Favours interventn 2
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Analysis 3.2. Comparison 3 Nonabsorbable antifungal agent versus no antifungal agent, Outcome 2 Proven
invasive fungal infection.
Review: Antifungal agents for preventing fungal infections in solid organ transplant recipients
Comparison: 3 Nonabsorbable antifungal agent versus no antifungal agent
Outcome: 2 Proven invasive fungal infection









Owens 1984 0/24 3/20 0.12 [ 0.01, 2.19 ]
0.002 0.1 1 10 500
Favours antifungal Favours control
Analysis 3.3. Comparison 3 Nonabsorbable antifungal agent versus no antifungal agent, Outcome 3 Proven
invasive fungal infections (azole-resistant Candida species).
Review: Antifungal agents for preventing fungal infections in solid organ transplant recipients
Comparison: 3 Nonabsorbable antifungal agent versus no antifungal agent
Outcome: 3 Proven invasive fungal infections (azole-resistant Candida species)









Owens 1984 0/24 0/23 Not estimable
0.1 0.2 0.5 1 2 5 10
Favours antifungal Favours control
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Analysis 3.4. Comparison 3 Nonabsorbable antifungal agent versus no antifungal agent, Outcome 4 Proven
invasive fungal infection (moulds).
Review: Antifungal agents for preventing fungal infections in solid organ transplant recipients
Comparison: 3 Nonabsorbable antifungal agent versus no antifungal agent
Outcome: 4 Proven invasive fungal infection (moulds)









Owens 1984 0/24 2/20 0.17 [ 0.01, 3.31 ]
0.005 0.1 1 10 200
Favours antifungal Favours control
Analysis 3.5. Comparison 3 Nonabsorbable antifungal agent versus no antifungal agent, Outcome 5 Proven
invasive fungal infection (azole-resistant Candida species and moulds).
Review: Antifungal agents for preventing fungal infections in solid organ transplant recipients
Comparison: 3 Nonabsorbable antifungal agent versus no antifungal agent
Outcome: 5 Proven invasive fungal infection (azole-resistant Candida species and moulds)









Owens 1984 0/24 2/20 0.17 [ 0.01, 3.31 ]
0.005 0.1 1 10 200
Favours antifungal Favours control
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Analysis 3.8. Comparison 3 Nonabsorbable antifungal agent versus no antifungal agent, Outcome 8
Superficial fungal infection.
Review: Antifungal agents for preventing fungal infections in solid organ transplant recipients
Comparison: 3 Nonabsorbable antifungal agent versus no antifungal agent
Outcome: 8 Superficial fungal infection









Owens 1984 2/24 10/20 0.17 [ 0.04, 0.67 ]
0.02 0.1 1 10 50
Favours antifungal Favours control
Analysis 3.11. Comparison 3 Nonabsorbable antifungal agent versus no antifungal agent, Outcome 11
Adverse effects requiring cessation.
Review: Antifungal agents for preventing fungal infections in solid organ transplant recipients
Comparison: 3 Nonabsorbable antifungal agent versus no antifungal agent
Outcome: 11 Adverse effects requiring cessation









Owens 1984 0/24 0/20 Not estimable
0.1 0.2 0.5 1 2 5 10
Favours antifungal Favours control
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Analysis 4.8. Comparison 4 Nonabsorbable antifungal agent versus another nonabsorbable antifungal
agent, Outcome 8 Superficial fungal infection.
Review: Antifungal agents for preventing fungal infections in solid organ transplant recipients
Comparison: 4 Nonabsorbable antifungal agent versus another nonabsorbable antifungal agent
Outcome: 8 Superficial fungal infection








1 Nystatin versus clotrimazole
Gombert 1987 0/28 0/32 Not estimable
Ruskin 1992 1/17 1/17 1.00 [ 0.07, 14.72 ]
0.05 0.2 1 5 20
Favours nystatin Favours clotrimazole
Analysis 4.9. Comparison 4 Nonabsorbable antifungal agent versus another nonabsorbable antifungal
agent, Outcome 9 Fungal colonisation.
Review: Antifungal agents for preventing fungal infections in solid organ transplant recipients
Comparison: 4 Nonabsorbable antifungal agent versus another nonabsorbable antifungal agent
Outcome: 9 Fungal colonisation








1 Nystatin versus clotrimazole
Ruskin 1992 2/17 2/17 1.00 [ 0.16, 6.30 ]
0.1 0.2 0.5 1 2 5 10
Favours nystatin Favours clotrimazole
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Analysis 4.11. Comparison 4 Nonabsorbable antifungal agent versus another nonabsorbable antifungal
agent, Outcome 11 Adverse effects requiring cessation.
Review: Antifungal agents for preventing fungal infections in solid organ transplant recipients
Comparison: 4 Nonabsorbable antifungal agent versus another nonabsorbable antifungal agent
Outcome: 11 Adverse effects requiring cessation








1 Nystatin versus nystatin
Gombert 1987 1/29 0/33 3.40 [ 0.14, 80.36 ]
0.01 0.1 1 10 100
Favours nystatin Favours clotrimazole
A D D I T I O N A L T A B L E S




















19. 17 and 18
MEDLINE (OVID) 1. antifungal agents/
2. exp clotrimazole/
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25. (echinocandin$ or caspofungin).tw.
26. (select$ adj5 decontam$).tw.
27. exp nystatin/
28. or/1-27
29. randomized controlled trial.pt.
30. controlled clinical trial.pt.




35. exp Evaluation studies/
36. exp clinical-trials/
37. clinical trial.pt.
38. (clin$ adj5 trial$).tw.




43. exp Research design/
44. or/29-43
45. animal.sh.
46. 44 not 45
47. 28 and 46
48. exp HIV/ or exp HIV infections/
49. exp leukopenia/
50. exp bone marrow transplantation/
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Table 1. Search strategies for electronic databases (Continued)
51. exp leukemia/ or exp lymphoma/
52. exp tinea/ or exp tinea versicolor/
53. or/48-52
54. 47 not 53
55. exp PRIMARY PREVENTION/
56. prevent$.tw.
57. exp ANTIBIOTIC PROPHYLAXIS/
58. prophyl$.tw.
59. or/55-58
60. 47 and 59
61. exp renal transplantation/ or liver transplantation/ or transplant$.tw.
62. 47 and 61
63. 60 or 62
EMBASE (OVID) 1.exp amphotericin b/
2. exp amphotericin b cholesterol sulfate/
3. exp amphotericin b deoxycholate/
4. exp amphotericin b derivative/
5. exp amphotericin b lipid complex/
6. exp amphotericin b methyl ester/
7. exp echinocandin b/


























Tortorano 1995 Unclear Unclear No Unclear No 3/75 (4%)
Lumbreras 1996 Yes (permuted
blocks)
Unclear No Unclear Yes 0/143 (0)
Meyers 1997 Unclear Unclear Yes Unclear No Unclear
Winston 1999 Yes (computer
generated)
Unclear Yes Yes Yes 24/236 (10%)
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Table 2. Quality assessment of included studies: liver transplant recipients (Continued)
Sharpe 2003 Unclear Yes (pharmacy
allocation)









Unclear Yes 2/131 (2%)
Tollemar 1995 Unclear Yes (pharmacy
allocation)
Yes Yes No 9/86 (10%)
Winston 2002 Unclear Unclear No Unclear Yes 16/304 (5%)
Ruskin 1992 Unclear Unclear No Unclear Yes 0/34 (0)















Patton 1994 Unclear Unclear No Unclear No 16/110 (15%)
Sobh 1995 Unclear Unclear No Unclear Yes 0/100 (0)
Owens 1984 Unclear Unclear Yes Unclear No 3/47 (6%)
Gombert 1987 Yes (computer
generated)
Unclear No Unclear No 2/60 (3%)
Keogh 1995 Unclear Unclear No Unclear Yes 0/43 (0)
Table 4. Subgroup and sensitivity analyses





0.38 (0.16 to 0.91)







0.29 (0.13 to 0.61)





0.07 (0 to 1.26)
0.45 (0.22 to 0.93)
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0.37 (0.13 to 1.03)





0.25 (0.12 to 0.51)
0.77 (0.43 to 1.39)
Analysis model Random effects
Fixed effect
0.39 (0.18 to 0.85)
0.41 (0.26 to 0.63)
Table 5. Applicability of meta-analysis results




Number avoided NNT to prevent 1
IFI




5 2 3 28











25 7 18 6
IFI = invasive fungal infection
WH A T ’ S N E W
Last assessed as up-to-date: 21 November 2005.
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Date Event Description
13 May 2009 Amended Contact details updated.
H I S T O R Y
Protocol first published: Issue 3, 2003
Review first published: Issue 3, 2004
Date Event Description
15 September 2008 Amended Converted to new review format.
22 November 2005 Amended New studies sought, but none found
C O N T R I B U T I O N S O F A U T H O R S
• EGP wrote the protocol, developed the search strategy, identified trials and coordinated trial results, data extraction, RevMan
data entry, and wrote final review
• ACW reviewed the protocol, identified trials, extracted data, and reviewed the final review
• TCS reviewed the protocol, identified trials, reviewed the results and the final review
• JCC reviewed the protocol, identified trials, reviewed the results and the final review
D E C L A R A T I O N S O F I N T E R E S T
• EGP: none declared
• ACW: none declared
• TCS: has advisory board involvement with Pfizer, has received unrelated project funding from Pfizer, Merck, and Gilead, and is
a member of the Mycology Interest Group of the Australasian Society for Infectious Diseases, which is sponsored by Gilead.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Organ Transplantation [mortality]; Antifungal Agents [∗therapeutic use]; Fluconazole [therapeutic use]; Immunocompromised Host;
Liver Transplantation [mortality]; Mycoses [mortality; ∗prevention & control]; Randomized Controlled Trials as Topic
MeSH check words
Humans
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